Select Medical (SEM) Q1 2026 earnings review
Take-Private Deal Overshadows Continued Margin Erosion
Select Medical's Q1 results reveal a widening gap between top-line volume and bottom-line profitability. While consolidated revenue grew a respectable 5.0% YoY to $1.42B, Net Income plunged 14.7% and Adjusted EBITDA fell 6.5%. The underlying story remains a tale of two companies: the Rehabilitation Hospital (RH) segment is a booming growth engine (+15.1% EBITDA), while the Critical Illness (CIRH) and Outpatient (OR) segments suffer from reversing margins driven by Medicare cuts and operating costs. However, fundamental analysis takes a back seat to corporate action: the company agreed to a $16.50 per share take-private merger with WCAS, expected to close in mid-2026, effectively placing a floor under the stock and halting all share repurchases.
🐂 Bull Case
The RH segment is accelerating, with Q1 revenue up 14.5% and admissions jumping 13.0%. Operating margin expanded slightly to a highly profitable 23.0%, cementing it as the company's clear growth engine.
The definitive merger agreement at $16.50 per share mitigates fundamental downside risk. With HSR antitrust clearance already secured in late April, the path to a mid-2026 close looks clear.
🐻 Bear Case
Outside of Rehab, profitability is reversing. Critical Illness EBITDA fell 15.3% despite flat revenue, and Outpatient EBITDA fell 9.4%, reflecting structural pressure from labor, health insurance costs, and Medicare rates.
Management reaffirmed FY26 EBITDA guidance implying ~7.5% YoY growth. Achieving this after a 6.5% decline in Q1 requires a dramatic acceleration in profitability in the remaining quarters.
⚖️ Verdict: ⚪
Neutral. From a fundamental standpoint, the shrinking margins in two of three segments are highly concerning. However, the pending $16.50 cash acquisition shifts the investment thesis from operating performance to merger arbitrage.
Key Themes
The WCAS Take-Private Transaction
Operations are now secondary to the definitive merger agreement. Select Medical will be acquired by WCAS and members of the management team (including Executive Chairman Robert Ortenzio) for $16.50 per share in cash. The HSR waiting period expired on April 27, 2026, removing a key regulatory hurdle. As a result, capital allocation is frozen—no share repurchases occurred in Q1.
Rehabilitation Hospitals: The Definitive Growth Engine
The RH segment is accelerating rapidly. Revenue surged 14.5% YoY to $351.9M, driven by a 13.0% increase in admissions and a 12.5% increase in patient days. Crucially, the volume growth did not dilute profitability; Adjusted EBITDA margin ticked up to 23.0% from 22.9%. This segment benefits from a robust joint-venture pipeline with major health systems, historically adding hundreds of beds annually.
Critical Illness Margins Continue Reversing
The CIRH segment (the company's largest by revenue) is stagnating. Revenue was virtually flat (+0.3%) at $638.8M, but Adjusted EBITDA plunged 15.3% YoY to $73.4M. The margin compressed significantly from 13.6% to 11.5%. Management has previously cited structural macro headwinds—specifically the soaring CMS high-cost outlier threshold—as the primary culprit squeezing profitability from high-acuity patients.
Outpatient Division Struggles to Recover
Outpatient operations remain under severe pressure. While patient visits grew a healthy 4.5%, revenue per visit remained entirely flat at $102. Consequently, Adjusted EBITDA fell 9.4% to $22.0M, driving margins down to a meager 6.8% (from 7.9% in 25Q1 and 9.3% in 25Q2). The division has struggled to offset Medicare physician fee schedule cuts and unfavorable managed care payer mix shifts.
Corporate Costs Outpacing Revenue
A clear contradiction exists between top-line growth and expense control. General and Administrative (G&A) expenses surged 19.3% YoY to $39.4M, wildly outpacing the 5.0% revenue growth. This includes an $846,000 charge for take-private transaction costs, but even excluding that, corporate overhead is heavily dragging down consolidated operating income.
Technology & AI Optimization Initiatives
To combat margin compression in the Outpatient segment, the company has deployed a new scheduling module to improve therapist productivity. Furthermore, management previously confirmed active evaluation of AI for back-end billing processes and pilot programs for outpatient collections and virtual sitters, signaling a shift toward technology to offset wage inflation.
Macro Picture: Regulatory and Inflationary Headwinds
The company remains highly exposed to federal health policy. While a deferred 20% transmittal rule provided temporary relief in late 2025, the structural reality of Medicare rate cuts in the Outpatient sector and rising acuity thresholds in Critical Illness are permanent fixtures. Additionally, broad corporate health insurance cost spikes (which hit EBITDA by $15M in 25Q4) highlight ongoing inflationary labor risks.
Consistent Dividend While Awaiting Merger
Despite the suspension of the $1.0B share repurchase program due to the merger, the Board declared a standard $0.0625 per share quarterly dividend. Operating cash flow rebounded sharply to $37.9M in Q1 (reversing from a $3.5M cash burn in 25Q1), safely covering the ~$7.8M dividend payout.
Other KPIs
Decelerating. Dropped 12.7% YoY from $112.7 million. The 6.3% increase in cost of services ($1.24B) paired with the 19.3% spike in G&A easily erased the $68.3M gain in top-line revenue.
Reversing positively. A major bright spot in the quarter, improving significantly from a cash burn of $3.5M in 25Q1. This was aided by better working capital management, notably a $36M favorable swing in accounts payable and accrued expenses.
Guidance
Stable. The midpoint of $5.7B implies approximately 4.5% YoY growth over FY25's $5.45B. This is highly achievable given Q1 already delivered 5.0% YoY growth.
Accelerating implied trajectory. The midpoint of $530M requires roughly 7.5% YoY growth over FY25 ($493.2M). Because 26Q1 EBITDA actually declined 6.5% YoY, management is relying on a massive margin recovery or easier comparable base in the second half of the year to hit this target.
Accelerating vs FY25's $1.16. Reaffirmed from February estimates, assuming no changes to the share count due to the frozen buyback program.
Key Questions
Bridge to FY26 EBITDA Guidance
With Q1 Adjusted EBITDA declining 6.5% year-over-year, reaffirming the FY26 guidance implies a steep acceleration in profitability for the remainder of the year. What specific operational levers give you confidence in bridging this gap?
Outpatient Cost Pressures
Outpatient revenue per visit remained completely flat at $102 while margins compressed to 6.8%. Have the unexpected health insurance spikes seen in late 2025 stabilized, and when will the new scheduling module begin materially improving therapist productivity?
Contingency Operations
Should the pending WCAS merger face unexpected delays or regulatory hurdles prior to the expected mid-2026 close, would the Board immediately reinstate the $1.0 billion share repurchase authorization to support the stock?